Recombinant adenoviral vector and method of use

• US 7,041,284 B2
• Filed: 10/28/1997
• Issued: 05/09/2006
• Est. Priority Date: 10/25/1993
• Status: Expired due to Fees

• Current Assignee: Canji Inc. (Merck & Co., Inc.)
• Original Assignee: Canji Inc. (Merck & Co., Inc.)
• Inventors: Maneval, Daniel C., Wills, Ken N., Gregory, Richard J.
• Primary Examiner(s): Guzo, David
• Application Number:
  US08/958,570
• Publication Number:
  US 20010016192A1
• Time in Patent Office: 3,115 Days
• Field of Search: 424/93.1, 424/93.2, 424/93.6, 435/320.1, 435/69.1, 435/455, 435/456, 435/457, 435/325, 435/172.1, 435/172.3, 455/455, 455/456, 455/457, 455/69.1, 455/320.1, 455/325
• US Class Current: 424/93.2
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/4746 p53
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/10343 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2830/008 cell type or tissue specific enhancer/promoter combination
• CPC Class Codes: C12N 2830/85 mammalian
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine dinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective.)

Claims

1. A method for obtaining expression of a tumor suppressor gene in a tumor cell in a mammal in vivo, wherein the tumor cell is caused by the absence of a tumor suppressor gene or the presence of a pathologically mutated tumor suppressor gene, the method comprising:

contacting the tumor cell with an effective amount of a replication-deficient recombinant adenovirus expression vector comprising;

a) a partial or total deletion of a protein IX-encoding DNA sequence, and b) a gene encoding a foreign protein having a tumor suppressive function, wherein said contacting comprises intratumoral, peritumoral or intravesicular injection of the recombinant adenenovirus expression vector under suitable conditions such that the foreign protein is expressed in the tumor cell.

3. The method of claim 1 or 2, wherein the tumor suppressor gene encodes a protein selected from the group p53, p21, p16, Rb, Wilm'"'"'s tumor WT1 protein, h-NUC, mitosin and mito and p21.

4. The method of claim 1 or 2, wherein the tumor suppressor gene encodes p53.

5. The method of claim 1 or 2, wherein the gene is a suicide gene.

6. The method of claim 1 or 2, wherein the tumor cell is a member selected from the group consisting of non-small cell lung cancer, small cell lung cancer, hepatocarcinoma, melanoma, retinoblastoma, breast tumor, colorectal carcinoma, leukemia, lymphoma, brain tumor, cervical carcinoma, sarcoma, prostate tumor, bladder tumor, tumor of the reticuloendothelial tissues, Wilm'"'"'s tumor, astrocytoma, glioblastoma, neuroblastoma, ovarian carcinoma, osteosarcoma, or renal cancer.

7. The method of claim 1 or 2, wherein deletion of the protein IX-encoding DNA sequence extends from about 3500 bp from the 5′

viral termini to about 4000 bp from the 5′

viral termmi.

8. The method of claim 1 or 2, wherein the recombinant adenovirus expression vector further comprises a deletion of a non-essential DNA sequence in adenovirus early region 3 or early region 4.

9. The method of claim 1 or 2, wherein the recombinant adenovirus expression vector further comprises a deletion of DNA sequences designated adenovirus E1a and E1b.

10. The method of claim 1 or 2, wherein the recombinant adenovirus expression vector further comprises a deletion of early region 3 or 4 and DNA sequences designated adenovirus E1a and E1b.

11. The method of claim 1 or 2, wherein the recombinant adenovirus expression vector is a Group C adenovirus selected from a serotype 1, 2, 5 or 6.

12. The method of claim 1 or 2, wherein the recombinant adenovirus expression vector is selected from the group consisting of A/C/N/53 and A/M/N/53.

13. The method of claim 1 or 2, further comprising administering a therapeutic agent that controls cell cycle progression and/or induces cell death.

14. The method of claim 1 or 2, wherein the mammal is a human.

15. The method of claim 10, wherein the recombinant adenovirus expression vector further comprises a deletion of up to forty nucleotides positioned 3′

to the site of the adenovirus E1a and E1b DNA sequence deletions, and the site of the partial or total deletion of the protein IX-encoding sequence, and wherein said foreign functional protein comprises a polyadenlyation signal.

2. A method of inhibiting the proliferation of a tumor cell in a mammal, wherein the tumor cell is caused by the absence of a tumor suppressor gene or the presence of a pathologically mutated tumor suppressor gene, the method comprising:

administering to the mammal an effective amount of a replication-deficient recombinant adenovirus expression vector comprising;

a) a partial or total deletion of a protein IX-encoding DNA sequence; and

b) a gene encoding a foreign functional protein having a tumor suppressive function under suitable conditions to the mammal, wherein said administering comprises intratumoral, peritumoral or intravesicular injection of the replication-deficient recombinant adenenovirus vector under suitable conditions such that the foreign functional protein is expressed in the tumor cell.

16. A method for obtaining expression of a suicide protein in a cell, the method comprising administering to the cell an effective amount of a recombinant adenovirus expression vector comprising:

a) a partial or total deletion of a protein IX-eneoding DNA sequence, and b) a gene encoding a suicide protein, wherein an mRNA encoding the suicide protein is produced by the cell.

17. A method for reducing the proliferation of a tumor cell in a mammal, the method comprising administering under suitable conditions an effective amount of an adenoviral expression vector comprising:

a) a partial or total deletion of a protein IX-encoding DNA sequence, and b) a gene encoding a suicide protein or a biologically active fragment thereof; and

a therapeutic agent that in the presence of the suicide protein is toxic to the tumor cell.

18. The method of claim 17, wherein the therapeutic agent is a thymidine kinase metabolite or a functional equivalent thereof.

19. The method of claim 17, wherein the thymidine kinase metabolite is ganciclovir or 6-methoxypurine arabinonucleoside or a functional equivalent thereof.

20. The method of claim 17, wherein the adenoviral expression vector is administered by injection into the tumor mass.

21. The method of claim 17, wherein the tumor cell is hepatocellular carcinoma.

22. The method of claim 17, wherein the adenoviral expression vector is administered directly into the hepatic artery of the subject.

23. The method of claim 17, wherein the suicide protein is a functional thymidine kinase protein, a functional E. coli DEO Δ

protein, or a functional cytosine deaminase protein.

24. The method of claim 17, wherein the recombinant adenovirus expression vector further comprises a deletion of a non-essential DNA sequence in adenovirus early region 3 or early region 4.

25. The method of claim 17, wherein the recombinant adenovirus expression vector further comprises a deletion of DNA sequences designated adenovirus E1a and E1b.

26. The method of claim 17, wherein the recombinant adenovirus expression vector further comprises a deletion of early region 3 or 4 and DNA sequences designated adenovirus E1a and E1b.

27. The method of claim 17, wherein the recombinant adenovirus expression vector is a Group C adenovirus selected from a serotype 1, 2, 5 or 6.

28. The method of claim 17, wherein the recombinant adenovirus expression vector is selected from the group consisting of A/C/N/53 or A/M/N/53.

29. The method claim 17, further comprising administering a therapeutic agent that controls cell cycle progression and/or induces cell death.

30. The method of claim 17, wherein the tumor cell is a human tumor cell.

31. A kit for reducing the proliferation of tumor cells comprising the components of the adenoviral expression vector of claim 17, a thymidine kinase metabolite or functional equivalent thereof, pharmaceutical carriers and instructions for the treatment of hepatocellular carcinoma using the kit components.

32. The method of claim 26, wherein the recombinant adenovirus expression vector further comprises a deletion of up to forty nucleotides positioned 3′

to the site of the adenovirus E1a and E1b DNA sequence deletions, and the site of the partial or total deletion of the protein IX-encoding sequence, and wherein said foreign functional protein comprises a polyadenlyation signal.